Why Mexico is the Ideal Destination for Near-Shore Clinical Research
Are you searching for a prime location to conduct clinical research, where pharmaceutical and medical device companies are achieving unparalleled success? Look no further than Mexico! With its large US-based patient population, genetically diverse communities, and stringent regulatory compliance, Mexico has emerged as a premier destination for clinical trials. Over 200 companies have conducted successful clinical trials in this country, including blue-chip multinationals and emerging pharmaceutical and medical device companies. In this blog, we'll delve into the unique advantages of conducting clinical trials in Mexico and introduce MYER's specialized approach to near-shore drug development. So, let's explore why Mexico should be at the top of your list for clinical research options!
Centralized patient base:
Mexico's large centralized patient population is one of the major factors contributing to high recruitment and retention rates in clinical trials. Furthermore, the rising demand for chronic disease treatments and motivated patient populations with limited access to healthcare services provide an attractive option for US-based companies to conduct clinical trials in Mexico.
Cost savings:
Conducting clinical trials in Mexico translates to significant cost savings over US-based studies due to fair market value differences and proximity travel to US cities. This makes Mexico an attractive option for US-based companies looking to save on costs without compromising on quality.
Improved recruitment/retention:
The diverse patient base in Mexico and high recruitment and retention rates contribute to improved trial success rates. Mexico's ethnology and etiology representative of genetically diverse populations also allows for a wider range of patient profiles to be included in clinical trials.
ICH/GCP quality:
Mexico's well-developed and rigorous ICH-GCP compliant regulatory landscape has attracted different levels of US FDA collaborative relationships, established an internationally renowned clinical-research infrastructure with growing capabilities, and fostered strong collaborations with academic and healthcare institutions. This results in high-quality clinical research that meets international standards.
In conclusion, Mexico shines as a strategic near-shore option for clinical research, offering an established clinical research ecosystem that presents multiple advantages for pharmaceutical and medical device companies seeking to achieve successful clinical trials.
MYER's experienced group of partners, advisors, and consultants can help your organization access these near-shore clinical research opportunities and expand into the Latin American market via partnering opportunities. By including Mexico in your clinical research strategy, you can maximize your ROI and achieve successful clinical trials.
So why limit your clinical research strategy to the United States alone? Expand your horizons with MYER and unlock the potential of Mexico's flourishing clinical research ecosystem. Contact us today to learn more about how we can help you achieve successful clinical trials and drive growth for your organization.
Unlock the secrets of Near Shore Clinical Research with our exclusive e-book. Download now and stay updated on the latest trends and insights. Don't forget to share your email with us to receive more valuable content!
Comments